ACSS3

Across TCGA pan-cancer cohorts, ACSS3 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ACSS3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ACSS3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ACSS3 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where ACSS3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACSS3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−1.227	<.001	12	view →
HNSC	Male	III,IV	−0.887	<.001	11	view →
LSCC	Male	II,III,IV	−1.294	<.001	9	view →
LUAD	Female	II,III,IV	−1.001	<.001	9	view →
PDAC	All	III,IV	−0.642	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ACSS3–CCRCC

Open the CCRCC breakdown →